HDSA Pacific Region

An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with encouraging early safety data. A pivotal trial is now planned for 2027 to figure out if this drug, brezosiran, can slow HD. buff.ly/SQeZtww

The FDA has accepted uniQure’s application for AMT-130, an experimental gene therapy for Huntington’s disease, and set a May 2027 decision date. Read the details here: buff.ly/kRb7cEr

The 2026 HD Patient, Family, and Caregiver Education Day in Los Angeles, CA, is scheduled for Sunday, November 15th, 2026, from 10:00 AM to 4:00 PM. The event starts with Registration and Breakfast at 9:00 AM. This event also includes lunch! Register here: buff.ly/VWrCkof

Join the HDSA Webinar on The PRECISE-HD Trial: A Phase 3 Study to Evaluate Pridopidine in HD. This presentation summarizes the Phase 3 PRECISE-HD study, what potential participation might involve, and where to find more information. Click here to register: buff.ly/Vhi3GkO

Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That’s the big question this study hopes to answer. buff.ly/mjsED3O

Scientists discovered that a specific type of brain cell becomes unusually quiet in Huntington’s disease. By restoring the activity of these cells in mice, they were able to rebalance brain circuits and improve movement. buff.ly/hIQGf4U

A change in one gene can disrupt thousands of others in HD. A study in pigs suggests an explanation: expanded huntingtin interferes with chemical marks on DNA. The same effect wasn’t seen in mice, showing that the animal model matters. buff.ly/DwrBabM

A change in one gene can disrupt thousands of others in HD. A study in pigs suggests an explanation: expanded huntingtin interferes with chemical marks on DNA. The same effect wasn’t seen in mice, showing that the animal model matters. buff.ly/DwrBabM

When someone with Huntington’s disease experiences new symptoms, is HD always the cause? Not necessarily. A new review explores catatonia, an uncommon condition that can cause changes that overlap with HD symptoms. Read the article here: buff.ly/iJwAie2

2026 HDSA Celebration of Hope Gala ticket sales end on Thursday, October 29th. Join us for an elegant afternoon honoring remarkable individuals and celebrating the strength of our Northern California Huntington’s disease community. buff.ly/aLms1Rr

HDSA advocated for a more efficient, accessible, predictable, and responsive clinical research system that meets the needs of people living with HD during a September 10 site visit to Beth Israel Deaconess Medical Center in Boston, MA. Details here: buff.ly/PMkBy6O

Watch HDSA’s recorded webinar with members of the Novartis clinical development team for an update on INVEST-HD, the Phase 3 trial evaluating votoplam for Huntington’s disease. Click here to watch: buff.ly/XbNtfr1

Join the new HDSA Research Webinar on November 12th at 11:00 AM EST. This presentation will summarize the Phase 3 PRECISE-HD study, what participation might involve, and where to find more information. Click here to register: buff.ly/rca997x

Getting “stuck” on a thought, action, or conversation can be a symptom of HD—not stubbornness. New research suggests perseveration may begin earlier than previously thought and highlights the value of caregiver perspectives. buff.ly/p9nDojR

Scientists discovered that a specific type of brain cell becomes unusually quiet in Huntington's disease. By restoring the activity of these cells in mice, they were able to rebalance brain circuits and improve movement. Read the full article: buff.ly/jpmj3DO

Join us for an unforgettable, immersive experience at the Blackhawk Museum for the 2026 Celebration of Hope Gala. RSVP Today: buff.ly/6is4xBg When: Sunday, November 8, 2026 12:00 PM – 3:00 PM PST Where: Blackhawk Museum 3700 Blackhawk Plaza Circle Danville, CA 94506

Getting “stuck” on a thought, action, or conversation can be a symptom of HD—not stubbornness. New research suggests perseveration may begin earlier than previously thought and highlights the value of caregiver perspectives. buff.ly/p9nDojR

HD researchers developed an AI-powered tool that analyzes a short counting task. Its speech measures reflected clinical scores and HD-related changes over time, suggesting it could be used as a remote monitoring tool in the future. buff.ly/Z4x3Fok

Join us as we celebrate the Jaffe Family Team Daisy 2026 (10 years after) as honorees at the 2026 Celebration of Hope Gala. Click here to register: buff.ly/6is4xBg

Join us on Sunday, November 8th, from 12–3 PM at the Blackhawk Museum in Danville, CA, for the Celebration of Hope Gala benefiting HDSA. Come together with the community to support individuals and families impacted by HD. Click here to register: buff.ly/6is4xBg